Panalba Case Study
Panalba Case Study
After taking the time to review this case and all of the facts presented to us we have come to a decision. In light of recent events, we have decided that the best solution for both our domestic and international markets is to stop the production of Panalba immediately, but allow what we have already made to be sold. We feel that we needed to make a unified choice for each of these markets because we feel so strongly about the safety of the consumers. We don’t feel that it would be right to unnecessarily compromise the safety of any of our consumers, no matter where they live. While we understand that our company needs to act in a socially responsible manner to ensure the safety of our consumers, we also know that we have economic responsibilities to our shareholders. This is why we felt that we needed to choose a solution that offered some type of compromise. While we did consider recalling Panalba & destroying it, after giving it much thought we ultimately decided against it. We feel our solution will better help protect the safety of our consumers while delaying any future profit losses. While we have taken into account and value the FDA’s opinion of Panalba we also value the opinions of the doctors who prescribe it. We feel that we need to make sure these doctors inform their patients of all of possible risks associated with taking the medication, that way they can make their own informed decision weather to stop taking Panalba abruptly or to take the time they need to wean off of Panalba before medications. We feel it is unfair to our consumers to abruptly stop providing Panalba, and that by allowing what we have to be sold we will be offering our consumers transitional period to wean off of Panalba and help remediate any adverse impact that switching medications too quickly may have on them. We plan to take this time to work on a new more effective Strategic Management plan that focuses on our long-term performance.
After taking the time to review this case and all of the facts presented to us we have come to a decision. In light of recent events, we have decided that the best solution for both our domestic and international markets is to stop the production of Panalba immediately, but allow what we have already made to be sold. We feel that we needed to make a unified choice for each of these markets because we feel so strongly about the safety of the consumers. We don’t feel that it would be right to unnecessarily compromise the safety of any of our consumers, no matter where they live. While we understand that our company needs to act in a socially responsible manner to ensure the safety of our consumers, we also know that we have economic responsibilities to our shareholders. This is why we felt that we needed to choose a solution that offered some type of compromise. While we did consider recalling Panalba & destroying it, after giving it much thought we ultimately decided against it. We feel our solution will better help protect the safety of our consumers while delaying any future profit losses. While we have taken into account and value the FDA’s opinion of Panalba we also value the opinions of the doctors who prescribe it. We feel that we need to make sure these doctors inform their patients of all of possible risks associated with taking the medication, that way they can make their own informed decision weather to stop taking Panalba abruptly or to take the time they need to wean off of Panalba before medications. We feel it is unfair to our consumers to abruptly stop providing Panalba, and that by allowing what we have to be sold we will be offering our consumers transitional period to wean off of Panalba and help remediate any adverse impact that switching medications too quickly may have on them. We plan to take this time to work on a new more effective Strategic Management plan that focuses on our long-term performance.